<DOC>
	<DOCNO>NCT01989325</DOCNO>
	<brief_summary>This Phase 2 study patient advance multiple myeloma receive either carfilzomib alone ( single-agent ) carfilzomib combination investigational study drug filanesib ( ARRY-520 ) . Patients follow determine effectiveness single-agent carfilzomib carfilzomib + filanesib treat myeloma . Patients allow crossover single-agent carfilzomib carfilzomib + filanesib disease progression occur . Approximately 75 patient US enrol study .</brief_summary>
	<brief_title>A Study Filanesib ( ARRY-520 ) Carfilzomib Patients With Advanced Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Proteasome Inhibitors</mesh_term>
	<criteria>Key Confirmed multiple myeloma measurable disease . Disease refractory last myeloma regimen . Patients must receive least 2 prior treatment regimen , include bortezomib IMiD ( e.g. , lenalidomide , thalidomide , pomalidomide ) . Induction therapy stem cell transplant Â± maintenance consider single regimen . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 within 14 day prior first dose study treatment . Adequate hematology , liver renal function laboratory value within 14 day prior first dose study treatment . Additional criterion exist . Key Prior treatment carfilzomib , filanesib , KSP inhibitor . Past current plasma cell leukemia . Primary amyloidosis ( amyloidosis associate multiple myeloma allow ) . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein skin change ) . Ongoing Grade 3 Grade 4 peripheral neuropathy , Grade 2 peripheral neuropathy pain despite appropriate intervention , within 28 day prior first dose study treatment . Autologous allogeneic stem cell bone marrow transplant within 3 month prior first dose study treatment . Concomitant malignancies previous malignancy ( multiple myeloma ) less 2year diseasefree interval time first dose study treatment . Patients adequately resect basal squamous cell carcinoma skin , carcinoma situ cervix breast , Stage 1 prostate cancer eligible irrespective time diagnosis . Known pulmonary hypertension severity . Concurrent cardiac disease , judgment Investigator , would make patient inappropriate study participation . Known positive serology human immunodeficiency virus ( HIV ) , active hepatitis B and/or hepatitis C. Acute active infection require treatment . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>